Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Debt to Equity: 2009-2025

Historic Debt to Equity for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to $0.24.

  • China Pharma Holdings' Debt to Equity fell 37.79% to $0.24 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.17, marking a year-over-year decrease of 22.39%. This contributed to the annual value of $0.33 for FY2024, which is 4.15% down from last year.
  • As of Q3 2025, China Pharma Holdings' Debt to Equity stood at $0.24, which was down 44.27% from $0.42 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Debt to Equity peaked at $1.08 during Q3 2022, and registered a low of $0.24 during Q3 2025.
  • Over the past 3 years, China Pharma Holdings' median Debt to Equity value was $0.37 (recorded in 2025), while the average stood at $0.40.
  • Its Debt to Equity has fluctuated over the past 5 years, first surged by 100.64% in 2022, then crashed by 63.43% in 2023.
  • Over the past 5 years, China Pharma Holdings' Debt to Equity (Quarterly) stood at $0.72 in 2021, then fell by 20.90% to $0.57 in 2022, then crashed by 39.98% to $0.34 in 2023, then declined by 4.15% to $0.33 in 2024, then plummeted by 37.79% to $0.24 in 2025.
  • Its Debt to Equity was $0.24 in Q3 2025, compared to $0.42 in Q2 2025 and $0.37 in Q1 2025.